Yong-Hua Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yong-Hua Gao has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Wei-Jie Guan
China-Portugal Artificial Intelligence and Public Health Technologies Joint Laboratory, Guangdong-Hong Kong-Macao Joint Laboratory of Respiratory Infectious Diseases, Guangdong Provincial Key Laboratory of Respiratory Disease Research, Guangzhou Medical University, Guangzhou, China
6 shared publications - Guo-Jun Zhang
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
5 shared publications Stefano Aliberti
Istituto di Ricovero e Cura a Carattere Scientifico di natura pubblica Humanitas Research Hospital, Rozzano, Milan, Italy
5 shared publicationsWei-Jie Guan
5 shared publicationsAnthony De Soyza
Population and Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom
4 shared publications- James Duncan Chalmers
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
4 shared publications
Latest Publications
- Open Access
- 13 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (9)
Symptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials
- 13 August 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (9)
Open AccessSymptoms and treatment response to florensocatib and inhaled tobramycin in bronchiectasis: Post hoc analysis of two randomized trials
- Open Access
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (6)
Bacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis: a post hoc analysis of the TORNASOL trial
Rationale: Inhaled aztreonam improves symptoms in bronchiectasis, with baseline bacterial load predicting therapeutic responses in Western populations. Evidence for inhaled tobramycin, a widely used alternative, remained limited in non-Western countries. The objectives of the present study were to investigate how baseline bacterial load modulates symptomatic responses to inhaled tobramycin, and to identify which symptoms improved most favourably in bronchiectasis. Methods: A post hoc analysis of the TORNASOL randomised, placebo-controlled trial included 357 adults with bronchiectasis and Pseudomonas aeruginosa in China. Patients received inhaled tobramycin or placebo in two 28-day on–off cycles, with follow-up to day 85. Sputum bacterial load was stratified as high (≥10 7 CFU·g −1 ), moderate (10 5 –10 6 CFU·g −1 ) and low (75% of high-load patients remaining in the same category. Compared with placebo, inhaled tobramycin yielded significant QoL-B-RSS improvements exceeding MCID in the high-load subgroup (mean difference 8.28, 95% CI 4.46–12.09; p<0.0001) and below the MCID in the moderate-load subgroup (mean difference 6.51, 95% CI 1.31–11.72; p=0.0065) at day 29, with improvements at day 85. Cough, sputum production/purulence and chest congestion were the symptoms exhibiting most favourable responses, particularly in the high-load subgroup. Conclusions: High bacterial load was associated with numerically greater symptomatic improvements to inhaled tobramycin in bronchiectasis. These hypothesis-generating findings warrant further investigation.
- 6 August 2026
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 12 (6)
Open AccessBacterial load, respiratory symptoms and inhaled antibiotic treatment in adults with bronchiectasis: a post hoc analysis of the TORNASOL trial
Rationale: Inhaled aztreonam improves symptoms in bronchiectasis, with baseline bacterial load predicting therapeutic responses in Western populations. Evidence for inhaled tobramycin, a widely used alternative, remained limited in non-Western countries. The objectives of the present study were to investigate how baseline bacterial load modulates symptomatic responses to inhaled tobramycin, and to identify which symptoms improved most favourably in bronchiectasis. Methods: A post hoc analysis of the TORNASOL randomised, placebo-controlled trial included 357 adults with bronchiectasis and Pseudomonas aeruginosa in China. Patients received inhaled tobramycin or placebo in two 28-day on–off cycles, with follow-up to day 85. Sputum bacterial load was stratified as high (≥10 7 CFU·g −1 ), moderate (10 5 –10 6 CFU·g −1 ) and low (75% of high-load patients remaining in the same category. Compared with placebo, inhaled tobramycin yielded significant QoL-B-RSS improvements exceeding MCID in the high-load subgroup (mean difference 8.28, 95% CI 4.46–12.09; p<0.0001) and below the MCID in the moderate-load subgroup (mean difference 6.51, 95% CI 1.31–11.72; p=0.0065) at day 29, with improvements at day 85. Cough, sputum production/purulence and chest congestion were the symptoms exhibiting most favourable responses, particularly in the high-load subgroup. Conclusions: High bacterial load was associated with numerically greater symptomatic improvements to inhaled tobramycin in bronchiectasis. These hypothesis-generating findings warrant further investigation.
- 4 June 2026
- Published by Wiley in Respirology
- Vol. 31 (8) , 774-775
Walking With Huffing: A Practical New Option for Airway Clearance During Bronchiectasis Exacerbations?
- 4 June 2026
- Published by Wiley in Respirology
- Vol. 31 (8) , 774-775
Walking With Huffing: A Practical New Option for Airway Clearance During Bronchiectasis Exacerbations?
- 23 June 2025
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 61 (11) , 657-659
Rethinking Pseudomonas aeruginosa in Bronchiectasis
- 23 June 2025
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 61 (11) , 657-659
Rethinking Pseudomonas aeruginosa in Bronchiectasis
- 23 April 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (5) , 2500518
Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis
Extract BECs are affected by infection and could be shaped by antibiotics. Inhaled antibiotics improve symptoms in bronchiectasis patients with P. aeruginosa infection, regardless of BECs levels.
- 23 April 2025
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 65 (5) , 2500518
Blood eosinophil counts, airway infections and inhaled antibiotic treatment in bronchiectasis
Extract BECs are affected by infection and could be shaped by antibiotics. Inhaled antibiotics improve symptoms in bronchiectasis patients with P. aeruginosa infection, regardless of BECs levels.
- Open Access
- 1 April 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (4) , 2640-2654
Phenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine
Background and Objective: Bronchiectasis, which was previously regarded as a rare condition, has recently attracted increased attention with advancements in research and therapeutic strategies. However, heterogeneity remains a major challenge in the management of bronchiectasis. This review aims to elucidate the concepts of phenotypes and endotypes, facilitate a deeper understanding of bronchiectasis complexity, and pave the way for personalized treatment approaches. Methods: The PubMed database was searched for relevant articles published in English between January 1990 and August 2024 using keywords “bronchiectasis”, “phenotype”, “endotype”, “diagnosis”, “disease management”, “complexity”, “eosino*”, “neutrop*”, and “precision medicine”. Key Content and Findings: We examined established clinical phenotypes, such as frequent exacerbator and chronic airway disease overlapped, significantly influencing prognosis and therapeutic management. The significance of etiology-based phenotyping was also discussed while emphasizing how identifying specific underlying causes can guide targeted therapies. We further explored recent advancements in characterising bronchiectasis endotypes, particularly those marked by neutrophilic and eosinophilic inflammation. These endotypes provide valuable insights into underlying pathophysiological mechanisms and guide the selection of clinical management strategies. Recent cluster analysis research has identified distinct inflammatory endotypes in bronchiectasis, thereby improving the understanding of disease progression and identifying potential therapeutic targets. Integrating molecular endotyping with clinical phenotyping provides a more comprehensive perspective of the disease, underscoring the necessity of a dual approach to effectively address its inherent heterogeneity. Furthermore, we emphasize the significance of identifying treatable traits within these frameworks, which can enhance the precision of treatment strategies and improve patient outcomes. By exploring the interplay between clinical phenotypes, endotypes, and patient-specific characteristics, this review highlights the potential for advancing precision medicine for bronchiectasis. Conclusions: Enhancing our understanding of bronchiectasis through these concepts is essential for developing tailored interventions that target the underlying biological mechanisms, thereby improving disease management and patients’ quality of life.
- 1 April 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (4) , 2640-2654
Open AccessPhenotypes and endotypes in bronchiectasis: a narrative review of progress toward precision medicine
Background and Objective: Bronchiectasis, which was previously regarded as a rare condition, has recently attracted increased attention with advancements in research and therapeutic strategies. However, heterogeneity remains a major challenge in the management of bronchiectasis. This review aims to elucidate the concepts of phenotypes and endotypes, facilitate a deeper understanding of bronchiectasis complexity, and pave the way for personalized treatment approaches. Methods: The PubMed database was searched for relevant articles published in English between January 1990 and August 2024 using keywords “bronchiectasis”, “phenotype”, “endotype”, “diagnosis”, “disease management”, “complexity”, “eosino*”, “neutrop*”, and “precision medicine”. Key Content and Findings: We examined established clinical phenotypes, such as frequent exacerbator and chronic airway disease overlapped, significantly influencing prognosis and therapeutic management. The significance of etiology-based phenotyping was also discussed while emphasizing how identifying specific underlying causes can guide targeted therapies. We further explored recent advancements in characterising bronchiectasis endotypes, particularly those marked by neutrophilic and eosinophilic inflammation. These endotypes provide valuable insights into underlying pathophysiological mechanisms and guide the selection of clinical management strategies. Recent cluster analysis research has identified distinct inflammatory endotypes in bronchiectasis, thereby improving the understanding of disease progression and identifying potential therapeutic targets. Integrating molecular endotyping with clinical phenotyping provides a more comprehensive perspective of the disease, underscoring the necessity of a dual approach to effectively address its inherent heterogeneity. Furthermore, we emphasize the significance of identifying treatable traits within these frameworks, which can enhance the precision of treatment strategies and improve patient outcomes. By exploring the interplay between clinical phenotypes, endotypes, and patient-specific characteristics, this review highlights the potential for advancing precision medicine for bronchiectasis. Conclusions: Enhancing our understanding of bronchiectasis through these concepts is essential for developing tailored interventions that target the underlying biological mechanisms, thereby improving disease management and patients’ quality of life.
- 1 April 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (4) , 506-514
Psychometric Validation and Determination of the Minimal Clinically Important Difference for the Bronchiectasis Health Questionnaire in Adults with Bronchiectasis
Rationale: The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered, and disease-specific instrument for measuring health-related quality of life in bronchiectasis. Objectives: We sought to investigate the psychometric properties of a simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments. Methods: A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection and a cross-sectional observational cohort of 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test–retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response. Results: There were significant positive correlations between scores on the BHQ and those on the Quality of Life–Bronchiectasis Respiratory Symptom Scale, with correlation coefficients of 0.698 in the trial cohort and 0.567 in the clinical cohort (both Ps < 0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both forced expiratory volume in 1 second percent predicted and exacerbation frequency within the previous year. In the trial cohort, the BHQ demonstrated excellent internal consistency (Cronbach’s α = 0.893) and test–retest reliability (intraclass correlation coefficient = 0.853). An 8-point improvement in scores on the Quality of Life–Bronchiectasis Respiratory Symptom Scale corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points. Conclusions: The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.
- 1 April 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (4) , 506-514
Psychometric Validation and Determination of the Minimal Clinically Important Difference for the Bronchiectasis Health Questionnaire in Adults with Bronchiectasis
Rationale: The Bronchiectasis Health Questionnaire (BHQ) is a concise, self-administered, and disease-specific instrument for measuring health-related quality of life in bronchiectasis. Objectives: We sought to investigate the psychometric properties of a simplified Mandarin BHQ and determine the minimum clinically important difference (MCID) as a reliable clinical endpoint for assessing the efficacy of bronchiectasis treatments. Methods: A longitudinal, randomized controlled trial cohort of 357 patients treated with tobramycin inhalation solution or saline inhalation for Pseudomonas aeruginosa infection and a cross-sectional observational cohort of 436 patients with bronchiectasis were analyzed. Psychometric analyses encompassed convergent validity, known-groups validity, internal consistency, test–retest reliability, and responsiveness. Both anchor-based and distribution-based approaches were utilized to calculate the MCID for therapeutic response. Results: There were significant positive correlations between scores on the BHQ and those on the Quality of Life–Bronchiectasis Respiratory Symptom Scale, with correlation coefficients of 0.698 in the trial cohort and 0.567 in the clinical cohort (both Ps < 0.0001). Known-groups validity indicated significant differences in BHQ scores stratified by baseline Bronchiectasis Severity Index. BHQ scores correlated modestly with both forced expiratory volume in 1 second percent predicted and exacerbation frequency within the previous year. In the trial cohort, the BHQ demonstrated excellent internal consistency (Cronbach’s α = 0.893) and test–retest reliability (intraclass correlation coefficient = 0.853). An 8-point improvement in scores on the Quality of Life–Bronchiectasis Respiratory Symptom Scale corresponded to a mean increase of 5.49 points in BHQ scores after 4-week treatment. The MCID for BHQ was consistently 3 points. Conclusions: The BHQ (MCID: 3 points) represents a clinically meaningful tool for evaluating therapeutic intervention outcomes and patient-centered outcomes in patients with bronchiectasis.
- 1 July 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (1) , 77-86
Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort Study
Rationale: Bronchiectasis is characterized by acute exacerbations, but the biological mechanisms underlying these events are poorly characterized. Objectives: To investigate the inflammatory and microbial characteristics of exacerbations of bronchiectasis. Methods: A total of 120 patients with bronchiectasis were enrolled and presented with acute exacerbations within 12 months. Spontaneous sputum samples were obtained during a period of clinical stability and again at exacerbation before receipt of antibiotic treatment. A validated rapid PCR assay for bacteria and viruses was used to classify exacerbations as bacterial, viral, or both. Sputum inflammatory assessments included label-free liquid chromatography-tandem mass spectrometry and measurement of sputum cytokines and neutrophil elastase activity. 16 s rRNA sequencing was used to characterize the microbiome. Measurements and Main Results: Bronchiectasis exacerbations showed profound molecular heterogeneity. At least one bacterium was identified in 103 samples (86%), and a high bacterial load (total bacterial load > 107 copies/g) was observed in 81 patients (68%). Respiratory viruses were identified in 55 (46%) patients, with rhinovirus being the most common virus (31%). PCR testing was more sensitive than culture. No consistent change in the microbiome was observed at exacerbation. Exacerbations were associated with increased neutrophil elastase, proteinase-3, IL-1β, and CXCL8. These markers were particularly associated with bacterial and bacterial plus viral exacerbations. Distinct inflammatory and microbiome profiles were seen between different exacerbation subtypes, including bacterial, viral, and eosinophilic events in both hypothesis-led and hypothesis-free analysis using integrated microbiome and proteomics, demonstrating four subtypes of exacerbation. Conclusions: Bronchiectasis exacerbations are heterogeneous events with contributions from bacteria, viruses, and inflammatory dysregulation.
- 1 July 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (1) , 77-86
Endotypes of Exacerbation in Bronchiectasis: An Observational Cohort Study
Rationale: Bronchiectasis is characterized by acute exacerbations, but the biological mechanisms underlying these events are poorly characterized. Objectives: To investigate the inflammatory and microbial characteristics of exacerbations of bronchiectasis. Methods: A total of 120 patients with bronchiectasis were enrolled and presented with acute exacerbations within 12 months. Spontaneous sputum samples were obtained during a period of clinical stability and again at exacerbation before receipt of antibiotic treatment. A validated rapid PCR assay for bacteria and viruses was used to classify exacerbations as bacterial, viral, or both. Sputum inflammatory assessments included label-free liquid chromatography-tandem mass spectrometry and measurement of sputum cytokines and neutrophil elastase activity. 16 s rRNA sequencing was used to characterize the microbiome. Measurements and Main Results: Bronchiectasis exacerbations showed profound molecular heterogeneity. At least one bacterium was identified in 103 samples (86%), and a high bacterial load (total bacterial load > 107 copies/g) was observed in 81 patients (68%). Respiratory viruses were identified in 55 (46%) patients, with rhinovirus being the most common virus (31%). PCR testing was more sensitive than culture. No consistent change in the microbiome was observed at exacerbation. Exacerbations were associated with increased neutrophil elastase, proteinase-3, IL-1β, and CXCL8. These markers were particularly associated with bacterial and bacterial plus viral exacerbations. Distinct inflammatory and microbiome profiles were seen between different exacerbation subtypes, including bacterial, viral, and eosinophilic events in both hypothesis-led and hypothesis-free analysis using integrated microbiome and proteomics, demonstrating four subtypes of exacerbation. Conclusions: Bronchiectasis exacerbations are heterogeneous events with contributions from bacteria, viruses, and inflammatory dysregulation.
- 1 March 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (3) , 393-401
Quality-of-Life Bronchiectasis Respiratory Symptom Scale Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study
Rationale: The relationship between symptoms, measured using a validated disease-specific questionnaire, and longitudinal exacerbation risk has not been demonstrated in bronchiectasis. Objectives: The aim of this study is to investigate whether baseline symptoms, assessed using the Quality-of-Life Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS) and its individual component scores, could predict future exacerbation risk in patients with bronchiectasis. Methods: The study included 436 adults with bronchiectasis from three tertiary hospitals. Symptoms were measured using the QoL-B-RSS, with scores ranging from 0 to 100, where lower scores indicated more severe symptoms. We examined whether symptoms as continuous measures were associated with the risk of exacerbation over 12 months. The analysis was also repeated for individual components of the QoL-B-RSS score. Results: The baseline QoL-B-RSS score was associated with an increased risk of exacerbations (rate ratio, 1.25 for each 10-point decrease; 95% confidence interval [CI], 1.15–1.35; P < 0.001), hospitalizations (rate ratio, 1.24; 95% CI, 1.05–1.43; P = 0.02), and reduced time to the first exacerbation (hazard ratio, 1.12; 95% CI, 1.03–1.21; P = 0.01) over 12 months, even after adjusting for relevant confounders, including exacerbation history. The QoL-B-RSS score was comparable to exacerbation history in its association with future frequent exacerbations (defined as three or more exacerbations per year) and hospitalization (area under the curve, 0.86 vs. 0.84; P = 0.46; and area under the curve, 0.81 vs. 0.83; P = 0.41, respectively). Moreover, patients with more severe symptoms in the majority of individual components of the QoL-B-RSS were more likely to experience exacerbations. Conclusions: Symptoms can serve as useful indicators for identifying patients at increased risk of exacerbation in bronchiectasis. Beyond relying solely on exacerbation history, a comprehensive assessment of symptoms could facilitate timely and cost-effective implementation of interventions for exacerbation prevention.
- 1 March 2024
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 21 (3) , 393-401
Quality-of-Life Bronchiectasis Respiratory Symptom Scale Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study
Rationale: The relationship between symptoms, measured using a validated disease-specific questionnaire, and longitudinal exacerbation risk has not been demonstrated in bronchiectasis. Objectives: The aim of this study is to investigate whether baseline symptoms, assessed using the Quality-of-Life Bronchiectasis Respiratory Symptom Scale (QoL-B-RSS) and its individual component scores, could predict future exacerbation risk in patients with bronchiectasis. Methods: The study included 436 adults with bronchiectasis from three tertiary hospitals. Symptoms were measured using the QoL-B-RSS, with scores ranging from 0 to 100, where lower scores indicated more severe symptoms. We examined whether symptoms as continuous measures were associated with the risk of exacerbation over 12 months. The analysis was also repeated for individual components of the QoL-B-RSS score. Results: The baseline QoL-B-RSS score was associated with an increased risk of exacerbations (rate ratio, 1.25 for each 10-point decrease; 95% confidence interval [CI], 1.15–1.35; P < 0.001), hospitalizations (rate ratio, 1.24; 95% CI, 1.05–1.43; P = 0.02), and reduced time to the first exacerbation (hazard ratio, 1.12; 95% CI, 1.03–1.21; P = 0.01) over 12 months, even after adjusting for relevant confounders, including exacerbation history. The QoL-B-RSS score was comparable to exacerbation history in its association with future frequent exacerbations (defined as three or more exacerbations per year) and hospitalization (area under the curve, 0.86 vs. 0.84; P = 0.46; and area under the curve, 0.81 vs. 0.83; P = 0.41, respectively). Moreover, patients with more severe symptoms in the majority of individual components of the QoL-B-RSS were more likely to experience exacerbations. Conclusions: Symptoms can serve as useful indicators for identifying patients at increased risk of exacerbation in bronchiectasis. Beyond relying solely on exacerbation history, a comprehensive assessment of symptoms could facilitate timely and cost-effective implementation of interventions for exacerbation prevention.
- Open Access
- 1 January 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (1)
A phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution forPseudomonas aeruginosaeradication in bronchiectasis: ERASE
ChronicPseudomonas aeruginosa(PA) infection significantly contributes to morbidity and mortality in bronchiectasis patients. Initiating antibiotics early may lead to the eradication of PA. Here we outline the design of a trial (ERASE;NCT06093191) assessing the efficacy and safety of inhaled tobramycin, alone or with oral ciprofloxacin, in bronchiectasis patients with a new isolation of PA. This multicentre, 2×2 factorial randomised, double-blind, placebo-controlled, parallel-group trial includes a 2-week screening period, a 12-week treatment phase (with a combination of ciprofloxacin or a placebo at initial 2 weeks) and a 24-week follow-up. 364 adults with bronchiectasis and a new PA isolation will be randomly assigned to one of four groups: placebo (inhaled saline and ciprofloxacin placebo twice daily), ciprofloxacin alone (750 mg ciprofloxacin and inhaled saline twice daily), inhaled tobramycin alone (inhaled 300 mg tobramycin and ciprofloxacin placebo twice daily) or a combination of both drugs (inhaled 300 mg tobramycin and 750 mg ciprofloxacin twice daily).The primary objective of this study is to assess the proportion of patients successfully eradicating PA in each group by the end of the study. Efficacy will be evaluated based on the eradication rate of PA at other time points (12, 24 and 36 weeks), the occurrence of exacerbations and hospitalisations, time to first pulmonary exacerbations, patient-reported outcomes, symptom measures, pulmonary function tests and the cost of hospitalisations.To date no randomised trial has evaluated the benefit of different PA eradication strategies in bronchiectasis patients. The ERASE trial will therefore generate crucial data to inform future clinical guidelines.
- 1 January 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (1)
Open AccessA phase 4 multicentre, 2×2 factorial randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of tobramycin inhalation solution forPseudomonas aeruginosaeradication in bronchiectasis: ERASE
ChronicPseudomonas aeruginosa(PA) infection significantly contributes to morbidity and mortality in bronchiectasis patients. Initiating antibiotics early may lead to the eradication of PA. Here we outline the design of a trial (ERASE;NCT06093191) assessing the efficacy and safety of inhaled tobramycin, alone or with oral ciprofloxacin, in bronchiectasis patients with a new isolation of PA. This multicentre, 2×2 factorial randomised, double-blind, placebo-controlled, parallel-group trial includes a 2-week screening period, a 12-week treatment phase (with a combination of ciprofloxacin or a placebo at initial 2 weeks) and a 24-week follow-up. 364 adults with bronchiectasis and a new PA isolation will be randomly assigned to one of four groups: placebo (inhaled saline and ciprofloxacin placebo twice daily), ciprofloxacin alone (750 mg ciprofloxacin and inhaled saline twice daily), inhaled tobramycin alone (inhaled 300 mg tobramycin and ciprofloxacin placebo twice daily) or a combination of both drugs (inhaled 300 mg tobramycin and 750 mg ciprofloxacin twice daily).The primary objective of this study is to assess the proportion of patients successfully eradicating PA in each group by the end of the study. Efficacy will be evaluated based on the eradication rate of PA at other time points (12, 24 and 36 weeks), the occurrence of exacerbations and hospitalisations, time to first pulmonary exacerbations, patient-reported outcomes, symptom measures, pulmonary function tests and the cost of hospitalisations.To date no randomised trial has evaluated the benefit of different PA eradication strategies in bronchiectasis patients. The ERASE trial will therefore generate crucial data to inform future clinical guidelines.